Clinical Trial

DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death

Study acronym: ANDROMEDA
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to evaluate if there are differences in DNA methylation of peripheral blood in patients with Brugada syndrome and healthy subjects. The main question it aims to answer is: Does DNA methylation changes distinguish Brugada patients from healthy controls? Does DNA methylation changes distinguish Brugada patients with high versus low risk of sudden cardiac death?
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-15.
Trial Details
NCT Number NCT06888271
Lead Sponsor University of Campania Luigi Vanvitelli
Conditions Brugada Syndrome, Sudden Cardiac Death Due to Cardiac Arrhythmia
Enrollment 10 participants
Start Date 2025-05
Primary Completion 2026-02 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-03-24